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Background
Dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides
are the main alkamides in Echinacea preparations, which
have been demonstrated to possess biological activities in
various bio-assays, such as immune-modulating activities
and effects on cannabinoid receptors [1]. Therefore, the
evaluation of systemic availability of these active plant
constituents is a major prerequisite for the interpretation
of in vitro pharmacological testing. This study assessed the
absolute and relative bioavailabilities of dodeca-
2E,4E,8E,10E/Z-tetraenoic acid isobutylamides
(tetraenes) administered as pure compounds or as an
Echinacea purpurea root extract preparation.
Methods
Ten rats received 0.75 mg/kg dodeca-2E,4E,8E,10E/Z-
tetraenoic acid isobutylamides orally, pure and within
158.6 mg/kg Echinacea purpurea extract, or intravenously
to compare the absorption and pharmacokinetic proper-
ties. Pharmacokinetic parameters and bioavailability data
of tetraenes were obtained by non-compartmental analy-
sis (NCA) using WinNonlin® 5.2 software.
Results
Mean dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutyla-
mide plasma area under the concentration-time curve
(AUC0-∞ per dose) was 3.2 ± 0.3 min·ng/mL/μg and 1.0 ±
0.2 min·ng/mL/μg after i.v. and oral administration,
respectively, and 1.5 ± 0.2 min·ng/mL/μg after oral
administration of the Echinacea root extract. The absolute
bioavailability of dodeca-2E,4E,8E,10E/Z-tetraenoic acid
isobutylamides was 29%, which was increased to 47%
(1.6 fold) by the administration of an Echinacea extract.
The relative bioavailability was over 100%.
Conclusion
Administration of a whole Echinacea  extract increases
blood exposure with no impact on Cmax. The high area
under the curve concentration resulted in a longer elimi-
nation half-life with 123 min in comparison to 36 min
after administration of the pure dodeca-2E,4E,8E,10E/Z-
tetraenoic acid isobutylamides. The approximately 2-fold
higher percentage of relative bioavailability achieved with
the Echinacea root extract resulted in a 3.4 and 3.6 times
higher terminal elimination half-life and mean residence
time (MRT), respectively. A rapid absorption followed by
a slower elimination phase was observed.
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